NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Abstract Background NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysiological hallmarks including excessive pulmonary vasoconstriction, va...

Full description

Bibliographic Details
Main Authors: Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Pulmonary Medicine
Subjects:
Thromboxane
Prostanoid
Thromboxane receptor antagonist
Pulmonary arterial hypertension
PAH
Monocrotaline
Online Access:http://link.springer.com/article/10.1186/s12890-020-1113-2

Internet

http://link.springer.com/article/10.1186/s12890-020-1113-2

Similar Items